AstraZeneca (LON:AZN) Rating Reiterated by Credit Suisse Group

AstraZeneca (LON:AZN)‘s stock had its “outperform” rating restated by equities research analysts at Credit Suisse Group in a report issued on Tuesday, February 20th. They presently have a GBX 5,800 ($80.13) price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s target price would suggest a potential upside of 21.72% from the company’s current price.

A number of other research analysts have also issued reports on the company. Berenberg Bank reiterated a “buy” rating and set a GBX 5,800 ($80.13) price target on shares of AstraZeneca in a research report on Wednesday, November 1st. Deutsche Bank reiterated a “buy” rating and set a GBX 5,600 ($77.37) price target on shares of AstraZeneca in a research report on Wednesday, November 1st. Kepler Capital Markets boosted their price target on AstraZeneca from GBX 5,200 ($71.84) to GBX 5,250 ($72.53) and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Investec upped their price objective on AstraZeneca from GBX 4,900 ($67.70) to GBX 5,500 ($75.99) and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Citigroup restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, November 8th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of GBX 5,199.70 ($71.84).

Get AstraZeneca alerts:

Shares of AstraZeneca (LON:AZN) traded down GBX 18 ($0.25) during midday trading on Tuesday, hitting GBX 4,765 ($65.83). The stock had a trading volume of 1,547,547 shares, compared to its average volume of 2,310,000. AstraZeneca has a 1-year low of GBX 4,260 ($58.86) and a 1-year high of GBX 5,520 ($76.26). The company has a market cap of $60,110.00 and a P/E ratio of 2,836.31.

In other news, insider Philip A. J. Broadley purchased 415 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was purchased at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).

COPYRIGHT VIOLATION NOTICE: “AstraZeneca (LON:AZN) Rating Reiterated by Credit Suisse Group” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/astrazeneca-azn-receives-outperform-rating-from-credit-suisse-group.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.